Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Megadott ok: Due to the KoreaFDA issue
A legfontosabb adatok
- Fázis
- 1/2. fázis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- Yae-Jean Kim
- Azonosító
- NCT02346617
- A regiszteradat frissítve
- 2020. március 20.
- Eredeti leírás
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.A teljes eredeti leírásKevesebb
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.
Bevonási feltételek: Less than 66 years old Allogeneic HCT recipients who received stem cells from related CMV positive serology donors; AND recipients have persistent CMV infection more than 2 weeks on antiviral treatment.
Kizáró feltételek: HCT recipients with severe graft versus host disease, grade 3 or more; OR organ dysfunction (brain, heart, lung, liver, and kidney): altered mentality, extracorporeal membrane oxygenation, mechanical ventilator, increased liver enzymes 5 times above upper normal values, bilirubin level >3 mg/dL, CrCl < 30 mL/min.